PremiumThe FlyAptarGroup raises quarterly dividend ~7% to 48c per share AptarGroup initiated with an Overweight at KeyBanc AptarGroup: Strong Performance and Growth Potential Amid Temporary Challenges PremiumRatingsAptarGroup’s Consistent Financial Strength and Pharma Segment Growth Drive Buy Rating AptarGroup reports Q2 EPS $1.67, consensus $1.59 AptarGroup sees Q3 EPS $1.53-$1.61, consensus $1.65 PremiumThe FlyAptarGroup price target raised to $170 from $162 at Wells Fargo AptarGroup’s Strong Pharmaceutical Growth and Strategic Initiatives Drive Buy Rating AptarGroup’s Q1 2025 Results: Sales Dip, Pharma Grows 
